A large, dark blue silhouette of a human head in profile, facing right. Inside the head, a lighter blue, stylized brain is depicted with branching lines representing neural pathways. The background is a solid dark blue.

Clinical analysis of children presenting with ADEM with or without MOG-IgG

Linda Nguyen, MD, PhD
Assistant Professor

2024 Rare Neuroimmune Disorders Symposium

What is ADEM?

- Acute disseminated encephalomyelitis
- Rapid onset and widespread inflammation of the brain and spinal cord
- Occurs throughout the entire lifespan, though >90% of all cases happen in children
- Typically presents as monophasic disorder associated with multifocal neurological symptoms and encephalopathy
- A subgroup of patients are positive for MOG-IgG

Study aim

- To characterize in children presenting with ADEM, a) clinical and paraclinical features and b) outcomes associated with or without MOG-IgG

Participants

- Patients up to 18 years of age seen between 2017 and 2024 in the demyelinating disease clinic at Children's Health Dallas
- Diagnosed with ADEM
- Had serum MOG-IgG testing at disease onset

Demographics

- 38 children: 27 (71%) MOG positive, 11 (29%) MOG negative

Demographics


- 38 children: 27 (71%) MOG positive, 11 (29%) MOG negative

★ Age at onset
median (IQR), years


MOG+

5.0 (3.8-8.4)

Sex





Race/ethnicity




MOG-

8.3 (7.1-9.9)



Acute phase

Presenting symptoms







MRI

★ Optic nerve involvement




Spinal cord involvement

★ Posterior globe indentation

MOG+



MOG-




MRI lesion burden score

| Area of abnormality | Score |
|------------------------------------|--|
| Supratentorial white matter | 1 for 25% involvement 2 for 50% involvement 3 for 75% involvement 4 for near complete involvement (max 4 points) |
| Cortex | 1 for unilateral 2 for bilateral (max 2 points) |
| Deep gray matter | 1 |
| Brainstem | 1 |
| Cerebellum | 1 |
| Optic nerve | 1 |
| Spinal cord | 1 for each region of involvement (cervical, thoracic, lumbar/conus) (max 3 points) |
| Total (max) | 13 |


| Cumulative score | Burden level |
|------------------|--------------|
| 1-3 | Low |
| 4-6 | Medium |
| 7-9 | High |
| 10-13 | Very High |

MRI lesion burden score

MOG+




MOG-




Cerebral spinal fluid analysis

★ Total nucleated cells
>5/mm³


MOG+






Protein >45 mg/dL




★ Opening pressure
>28 mmH₂O



MOG-




Hospital course




Acute treatments

MOG+





MOG-



Recovery/follow-up phase

Outcomes



Degree of recovery

No/minimal improvement (<25% improved)

Significant remaining T2 lesions (25-50% improved)


Moderate remaining T2 lesions (50-75% improved)

Few remaining T2 lesions (>75% improved)


Complete resolution

MRI recovery ★



MOG+




MOG-



OCT




Optical Coherence Tomography (OCT)



Retinal layers


Retinal nerve fiber layer thickness



Example report from OCT


OCT with abnormal thinning ★

MOG+




N=14


Vision changes



MRI optic nerve involvement



MOG-



N=4

Summary

At presentation

| | | | |
|---|------|---|------|
| Increased intracranial pressure | MOG+ | > | MOG- |
| Optic nerve involvement | MOG+ | > | MOG- |
| CSF total nucleated cells >5/mm ³ | MOG+ | > | MOG- |

At follow-up

| | | | |
|--------------|------|---|------|
| MRI recovery | MOG+ | < | MOG- |
|--------------|------|---|------|

Summary

At presentation

| | | | |
|---|------|---|------|
| Increased intracranial pressure | MOG+ | > | MOG- |
| Optic nerve involvement | MOG+ | > | MOG- |
| CSF total nucleated cells >5/mm ³ | MOG+ | > | MOG- |

At follow-up

| | | | |
|--|------|---|------|
| MRI recovery | MOG+ | < | MOG- |
| Ongoing symptoms affecting function | MOG+ | ≡ | MOG- |
| | | | |

Summary

At presentation

| | | | |
|---|------|---|------|
| Increased intracranial pressure | MOG+ | > | MOG- |
| Optic nerve involvement | MOG+ | > | MOG- |
| CSF total nucleated cells >5/mm ³ | MOG+ | > | MOG- |

At follow-up

| | | | |
|--|------|---|------|
| MRI recovery | MOG+ | < | MOG- |
| Ongoing symptoms affecting function | MOG+ | ≅ | MOG- |
| Relapse | MOG+ | = | MOG- |

Summary

At presentation

| | | | |
|---|------|---|------|
| Increased intracranial pressure | MOG+ | > | MOG- |
| Optic nerve involvement | MOG+ | > | MOG- |
| CSF total nucleated cells >5/mm ³ | MOG+ | > | MOG- |

At follow-up

| | | | |
|--|------|---|------|
| MRI recovery | MOG+ | < | MOG- |
| Ongoing symptoms affecting function | MOG+ | ≅ | MOG- |
| Relapse | MOG+ | = | MOG- |
| OCT with abnormal thinning | MOG+ | > | MOG- |



Thank you!

Dr. Benjamin Greenberg
Dr. Cynthia Wang
Dr. Sumit Singh
Darrel Conger



Questions or
comments?